Document is current
Any future updates will be listed below
-
Authors
Xiong, Wenjun
Gao, Xueliang
Zhang, Tiantian
Jiang, Baishan https://orcid.org/0000-0001-6796-9500
Hu, Ming-Ming
Bu, Xia
Gao, Yang
Zhang, Lin-Zhou
Xiao, Bo-Lin
He, Chuan
Sun, Yishuang
Li, Haiou
Shi, Jie
Xiao, Xiangling
Xiang, Bolin
Xie, Conghua https://orcid.org/0000-0001-6623-9864
Chen, Gang https://orcid.org/0000-0003-3332-3511
Zhang, Haojian
Wei, Wenyi https://orcid.org/0000-0003-0512-3811
Freeman, Gordon J. https://orcid.org/0000-0002-7210-5616
Shu, Hong-Bing https://orcid.org/0000-0001-9102-3272
Wang, Haizhen https://orcid.org/0000-0003-3477-8673
Zhang, Jinfang https://orcid.org/0000-0001-8487-6007
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (31970732)
- License Information
-
More Information
Article History
Received: 29 July 2021
Accepted: 15 March 2022
First Online: 31 March 2022
Competing interests
: G.J.F. has patents/pending royalties on the PD-1/PD-L1 pathway from Roche, Merck MSD, Bristol-Myers-Squibb, Merck KGA, Boehringer-Ingelheim, AstraZeneca, Dako, Leica, Mayo Clinic, and Novartis. G.J.F. has served on advisory boards for Roche, Bristol-Myers-Squibb, Xios, Origimed, Triursus, iTeos, NextPoint, IgM, and Jubilant. G.J.F. has equity in Nextpoint, Triursus, Xios, and IgM. W.W. is a co-founder and consultant for the ReKindle Therapeutics. Other authors declare no competing interests.
